Given the small patient numbers, it is challenging to suggest a patient population that could derive a particular benefit from BI 860585 in combination with exemestane or paclitaxel; however, responses were seen in two patients with breast cancer, a patient population for which the combination of the mTOR inhibitor everolimus is approved in combination with exemestane. This evidence concerns the gene MTOR and breast carcinoma.